Reading view
C-terminal CD28 phosphorylation, pY218, modulates IL-2 secretion and therapeutic effect of CAR-T cells
ACC1 inhibition enhances BCG-induced trained immunity by reprogramming acetyl-CoA metabolism
Advanced iPSC-based modelling of LMNA-related congenital muscular dystrophy enables development of genetic therapies for muscle laminopathies
Integrin α7 defines a profibrotic adipose stromal population targeted for nanoparticle PAI-1 gene silencing in obesity
Triple-AAV intein-mediated gene therapy ameliorates dystrophic phenotype in MDC1A mice
Repurposing base editors for targeted knockin and simultaneous multiplex knockouts to generate allo-CAR T cells with minimal translocations
Repurposing triamterene as chloride intracellular channel 1 inhibitor via ligand-based approach for glioblastoma
Targeted antisense oligonucleotide therapy rescues PRPF31 expression in retinitis pigmentosa caused by a splicing mutation
Albedo Estimation via Latent Bridge Matching
Context operations to architecture modelling output from large language models and evaluation criteria for their use in systems engineering design
EVA-Bench: A New End-to-end Framework for Evaluating Voice Agents
PRIME-SVR: Physics-infoRmed Implicit Multi-Echo Slice-to-Volume Reconstruction for Fetal T2 mapping
AI research startup Listen Labs scrubbed a $1.5B funding round for Salesforce talks
Smartphone-Based Monitoring of Quality of Life and Adverse Events After Neurosurgery: Prospective Cohort Study
STAT+: ARPA-H to invest $62 million to develop FDA-authorized AI to help treat heart failure
ARPA-H, the government agency that funds cutting-edge health research, plans to commit $62.7 million to develop artificial intelligence bots that direct treatment of heart failure. Among the goals of the program, called ADVOCATE, is to produce partially autonomous AI devices authorized by the Food and Drug Administration to help treat patients, including assessing symptom severity, prescribing drugs, and ordering lab tests.
ARPA-H on Wednesday announced the first batch of awards to health tech companies Atman Health, UpDoc, Tempus AI, and teams from Stanford University, Duke University, and the Kaiser Permanente health system. ARPA-H may still fund additional teams. The amount committed for the first year is $33.7 million, and the remainder may be renegotiated up or down.
Many of the 6.7 million Americans with heart failure don’t get optimal treatment because of difficulty accessing specialists, and the hope is that AI agents developed with ARPA-H funding can help address the gap, especially in rural and other underserved settings.
Continue to STAT+ to read the full story…


© Adobe
“Small” Large Language Models in the Hospital: Evaluation Study on Real-World Data in a Resource-Constrained Setting
Highly efficient base editing at <i>PCSK9</i> and normal human embryo development
Nature, Published online: 09 September 2026; doi:10.1038/s41586-026-11118-x
Highly efficient base editing at PCSK9 and normal human embryo developmentIntegrated signatures define mutational processes in prostate cancer
Nature, Published online: 09 September 2026; doi:10.1038/s41586-026-10468-w
Eight integrated mutational footprints collectively explain the mutational processes in 85% of primary prostate cancer genomes.A global framework for artificial intelligence education in medicine: international working group recommendations
npj Digital Medicine, Published online: 09 September 2026; doi:10.1038/s41746-026-03197-x
A global framework for artificial intelligence education in medicine: international working group recommendations